evaluation to refine the initial improvement theory and thereby increase probabilities for implementation. Methods: The realist evaluation included a mixed-method design and style consisting of semi-structured interviews with patients (n = 5) and involved well being care professionals (n = 25), stakeholder meetings (n = two), and surveys (n = 114). The study was approved by the recognized medical ethical committee of MUMC+ and all participants gave verbal informed consent. Each quantitative and qualitative data had been extracted to make the content material of context-mechanism-outcomeconfigurations (CMOcs) crucial in ECS therapy. The study was funded by a grant from ZonMw, the Netherlands Organisation for Wellness Analysis and Improvement.934 of|ABSTRACTwas demonstrated in the APS Patient and DVT recanalization either partial or complete was shown on venous duplex inside the other five sufferers. No bleeding complications had been documented whilst on fondaparinux. TABLE 1 Patient qualities and evolution on treatmentPatient (sex, age, weight) Higher thrombotic risk conditionConclusions: In our case series, fondaparinux was a limb-saving and prospective life-saving solution when other regular methods of anticoagulation failed.Thrombotic illness and treatmentEvolution 1 month post fondaparinux initiation: reduction in mass size to 3.four mm, no additional embolic eventsFemale, 28y, 64 kgTriple positive APS Ischemic toe at 25y, PE (on Warfarin) at 26y, 1st pregnancy at 27y (on LMWH): placental abruption at 28 weeks and HELLP syndromeAt 33 weeks of 2nd pregnancy: developed a TIA even though on LMWH – LMWH dose increased 20 Elective delivery at 36 weeks 2 days post-partum: developed numerous cerebral microinfarcts – a different 20 LMWH improve (total 40 ) four days post-partum: found to possess a large mitral valve thrombus (21 x 9 mm) and worsening neurological symptoms – fondaparinux ten mg x 1, then 7.5 mg die x 25 days (with Warfarin bridging)Female, 30y, 92 BRD9 Inhibitor MedChemExpress kgHomozygous ThurnerfactorIn-stent left common iliac vein thrombosis on Warfarin (4 months post insertion) – switched to LMWH 30 days later: Left leg DVT progression – LMWH elevated 25 7 days later: Correct widespread femoral DVT – fondaparinux ten mg die x 14 months, followed by Warfarin Bilateral above-knee DVTs – started on LMWH 15 above weight-adjusted dose 7 months later: acute bilateral above-knee DVTs – fondaparinux 7.5 mg die x 5 months, followed by Apixaban Appropriate above-knee DVT began on LMWHV Leiden and GCN5/PCAF Activator Storage & Stability Maysyndrome DVT: diagnosed just after post-partum left frequent iliac vein stent was insertedDuplex 5 months post: patent right leg veins, partial DVT regression on the leftMale, 54y, 65 kgTesticular metastatic germ cell tumorDuplex five months post: bilateral partial recanalizationMale, 50y, 57 kgStage IV Pancreatic cancer3 weeks later: Acute left above-knee DVT – LMWH enhanced 30 two months later: Bilateral PEs – fondaparinux 7.5 mg die x 40 days (then died from cancer)Duplex 1 month post: partial recanalization of bilateral DVTsFemale, 61y, 63 kgHodgkin’s lymphomaCatheter-related subclavian DVT – started on UFH (about 40 000 units/24h for therapeutic PTT) After 3 days of UFH: DVT extension in axillary vein – fondaparinux 7.5 mg die x eight months Ideal above-knee DVT and PEs started on LMWH 10 months later: spontaneous thigh hematoma requiring transfusion, du-Duplex two months later: partial recanalizationweekpost:Male, 71y, 75 kgMultiple myelomaplex showed acute ideal above-knee DVT – IVC filter insertion and stopped anticoagulation 2 weeks later: Le